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ABSTRACT
Introduction: The aim of this study was to
evaluate the effect of short-term oral valproic
acid (VPA) on the vision and visual fields of
patients with retinitis pigmentosa (RP).
Methods: In this prospective, nonrandomized
trial, 10 patients (20 eyes) with established RP
were treated with oral VPA 500 mg/day for
3 months. Visual acuity was monitored using
the Snellen chart and values were converted
into Early Treatment Diabetic Retinopathy
Study chart and logarithm of the minimum
angle of resolution (logMAR) equivalents.
Visual field changes were evaluated using the
Humphrey visual field analyzer (30-2 SITA
standard test protocol).
Results: Mean visual acuity was significantly
improved from a pretreatment value of 20/72
(logMAR 0.560 ± 0.488) to 20/65 (logMAR
0.513 ± 0.422) after 3 months of treatment
(P = 0.006). Vision improved by at least one
line or more than one line in 10 eyes, and
remained stable in the other 10 eyes. Visual field
improvement was noted in nine eyes (P\0.05,
v2 test), nine showing no significant field
change and in two visual fields could not be
recorded due to poor vision.
Conclusion: Short-term (3-month) treatment
with VPA improves the vision and visual field
of patients with RP.
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INTRODUCTION
Retinitis pigmentosa (RP) is an unrelentingly
progressive disease of the retinal photoreceptors
that results in loss of visual field in the early stages
and subsequently loss of visual acuity. There are
currently no therapeutic agents that slow the
progression of this disease, and certainly none
that can restore vision in patients with RP.
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Contrary to our present understanding of the
incurable nature of RP, treatment with valproic
acid (VPA) has recently been claimed to be
beneficial in maintaining and improving the
vision and visual fields of patients with this
disease, based on results from a small pilot study
[1]. However, the scientific rationale for using
VPA to treat RP and the methodology of the
study have subsequently been questioned [2, 3].
Here we report the results from a short-term
study evaluating oral VPA for the treatment of
RP. The authors hypothesize that VPA acts as a
chaperon and stabilizes the retinal function
thereby preventing further deterioration in
visual field and acuity.
MATERIALS AND METHODS
In this prospective, nonrandomized trial, 10
patients (20 eyes) with established RP received
VPA 500 mg/day (Dicorate ER 500, Sun
Pharmaceuticals, India; equivalent to 500 mg of
divalproex sodium) for the duration of the study,
which is still ongoing. The study was approved
by the institution’s ethics committee and
conducted in accordance with the Declaration
of Helsinki and good clinical practice guidelines.
Informed consent was obtained from each
patient before initiating therapy. The study was
conducted at a single center. Baseline
investigations before the initiation of treatment
included complete blood count, liver function
tests, blood urea and serum creatinine
estimation, and abdominal ultrasound in
female patients to rule out polycystic ovarian
disease.
Patients male or female above the age of
16 years were included in the study. Patients
with other ocular diseases, or other concomitant
retinal diseases that could influence treatment
outcome, and patients who had undergone any
ocular surgery in the previous 6 months were
excluded from study entry. In addition, patients
with liver or renal dysfunction, as indicated by
laboratory investigations, patients with
neurological disease, and pregnant or lactating
women were excluded. Female patients were
specifically asked to practice birth control
methods if they were of reproductive age and
were informed of the potential teratogenic effect
of VPA.
Best-corrected visual acuity was recorded
using the Snellen visual acuity chart at baseline
and at 3 months of follow-up. An improvement
in visual acuity of at least one line was
considered to be an improvement; no change
denoted stable vision and loss of one line
denoted visual deterioration. Visual acuity was
converted into Early Treatment Diabetic
Retinopathy Study (ETDRS) chart and
logarithm of the minimum angle of resolution
(logMAR) equivalents using standard
conversion tables [4]. Visual field was recorded
using the Humphrey visual field analyzer (HVF)
(Humphrey visual analyzer II; Carl Zeiss, Dublin,
USA) in patients with at least 20/400 vision. The
30-2 SITA standard test protocol was performed
at baseline and at the third month of follow-up.
On the HVF glaucoma change probability
analysis (GCPA) print-out, conversion of a
location flagged initially with a black square
in HVF, indicating a complete scotoma
(equivalent to P = 0.05), which converted
follow-up to a seeing area was sought and
counted (opposite to the glaucoma progression
analysis). The following criteria defined the
visual field improvement with GCPA as
significant (adapted from the Early Manifest
Glaucoma Trial) [5–7]: presence of three or
more test locations, not necessarily
contiguous, that converted from complete
scotoma to a completely visible area at last
follow-up. Visual field analysis was performed as
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detailed above, carefully noting the points for
improvement. The presence of three or more
locations that converted from complete
scotoma to a completely visible area on the
30-2 SITA standard test at 3 months was
counted. No adverse events were recorded.
Statistical Analysis
Separate statistical analysis is not presented as it
is not a comparative study. In the Results
section the authors have reported the P value
for the visual acuity and fiields assessment
separately. The paired t test and v2 test have
also been reported.
RESULTS
Patients either male or female in the age group
16 years and above were included in the study.
The duration and the extent of RP were not
considered for the inclusion of patients in the
study. None of the patients had taken any
treatment before this study.
Visual Acuity
The mean pretreatment visual acuity was 20/72
(logMAR 0.560 ± 0.488) and the mean
posttreatment visual acuity at 3 months
improved to 20/65 (logMAR 0.513 ± 0.422).
The mean change in logMAR across all eyes
was a decrease of 0.047. This corresponded to a
positive change of five letters or one line in the
ETDRS chart at the third month of follow up,
which was statistically significant (P = 0.006)
compared to baseline.
Vision improved by at least one line or more
than one line in 10 eyes. Two eyes showed a
one-line improvement, one eye a two-line
improvement and four eyes a three-line
improvement. In three eyes, vision improved
substantially from light perception to 20/200
vision, from count fingers close to face to 20/40
vision and from 20/600 to 20/200 vision
(Table 1). Six eyes (three patients) had 20/20
vision pretreatment and this remained stable at
3 months. One patient had 20/200 vision in
both eyes and did not show any significant
change at the end of the study. A further two
eyes from two different patients had a visual
acuity of light perception, and this remained
unchanged at the end of follow-up. The right
eye of patient no. 1 who had only 20/240 vision
in her right eye improved to 20/200 at 3 months
after starting treatment (Fig. 1a, b).
Visual Fields
Visual field improvement was noted in nine
eyes (P\0.05, v2 test). Nine eyes showed a
significant field change, while in two eyes visual
field could not be recorded at baseline or at
3 months due to poor vision (Table 1). Three
eyes, left eye of patients 1 (Fig. 2) and 5 (Fig. 3),
and right eye of patient 10 (Fig. 4a, b) in which
baseline fields could not be assessed due to low
vision pretreatment had recordable visual fields
at the end of 3 months.
DISCUSSION
Any pharmacological agent with even minimal
therapeutic potential for the treatment of RP
generates interest because of the lack of
confirmed treatment and the inexorable
progression to blindness that occurs in patients
with the disease. However, newer therapies also
invite considerable criticism, and it is essential
to gather as much information as possible about
them. Therefore, the authors share the results of
their short-term study in this report.
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Looking into the results of the present study,
the role of VPA in stabilizing the visual field and
acuity cannot be ignored. The hypothesis of it
working as a chaperon and preventing the
further loss of functional retina can be well
noted.
While the mechanism of action of VPA in RP
still remains unclear, the short-term visual gain
achieved with the drug in this subset of patients
is encouraging. It is unlikely that the
considerable improvement in visual and
documented retinal sensitivity on visual field
examination are solely due to a placebo effect,
particularly with the persistent and progressive
visual loss as noted in most of the studies [8, 9].
It has been postulated that VPA acts as a
pharmacological chaperon to increase the yield
of properly folded RP mutant rhodopsins, inhibit
Table 1 Best corrected visual acuity and visual ﬁelds before treatment and at 3 months after treatment with VPA
Patient
SI. no.
Age (years) Sex VA at baseline VA at 3 months Points of ﬁeld
improvement
VPA dose, mg
(duration, months)Distance Near Distance Near
1 62 F OD 20/240 NR 20/200 N60 6 500
OS PL NR 20/200 N60 24 (8)
2 35 M OD 20/200 N36 20/200 N36 NIL 500
OS 20/200 N36 20/200 N36 NIL (3)
3 22 F OD 20/20 N6 20/20 N6 NIL 500
OS 20/20 N6 20/20 N6 NIL (3)
4 24 F OD 20/20 N6 20/20 N6 3 500
OS 20/20 N6 20/20 N6 NIL (3)
5 67 F OD PL NR PL NR NIL 500
OS CFCF NR 20/40 N36 13 (5)
6 47 M OD 20/120 N36 20/60 N36 11 500
OS 20/120 N36 20/60 N36 NIL (4)
7 48 M OD 20/200 N36 20/60 N18 6 500
OS 20/240 N60 20/120 N60 NIL (3)
8 23 M OD 20/20 N6 20/20 N6 NIL 500
OS 20/20 N6 20/20 N6 NIL (3)
9 44 M OD 20/60 N18 20/20 N6 5 500
OS 20/240 N60 20/80 N18 3 (3)
10 53 F OD 20/600 NR 20/200 NR 9 500
OS PL NR PL NR NIL (5)
Visual ﬁelds showing improvement after treatment with VPA
CFCF counting ﬁngers close to face, F female, M male, NR nonrecordable, PL perception of light, VA visual acuity,
VPA valproic acid
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levels of histone deacetylase, and inhibit the
inflammatory response pathway by the apoptosis
of microglial cells [10, 11]. In addition,
VPA downregulates complement proteins and
increases the level of various neurotrophic
factors. Together, these properties of VPA
Fig. 1 Right eye of patient no. 1 who had only 20/240 vision in her right eye (a), which improved to 20/200 at 3 months
after starting treatment (b). The progressive improvement is documented in the visual ﬁelds
Fig. 2 Left eye of patient no. 1 who had perception of
light pretreatment and nonevaluable visual ﬁelds. Three
months after starting treatment, visual acuity improved to
20/200 and the visual ﬁeld was documented. The total
number of visual ﬁeld points gained was 24
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Fig. 3 Left eye of patient no. 5 who had counting ﬁngers
close to face, which improved to 20/40 3 months after
starting treatment. The ﬁeld report at 3 months after
starting treatment shows signiﬁcant improvement.
The total number of visual ﬁeld points gained was 13
Fig. 4 a Right eye of patient no. 10 who had 20/600
vision, which improved to 20/200 3 months after starting
treatment. b The second Humphrey visual ﬁeld analyzer
printout shows signiﬁcant improvement. The total number
of visual ﬁeld points gained was 9
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possibly result in the rescue of some of the
borderline photoreceptors (damaged or yet to be
damaged), thereby improving the visual field.
In a similar pilot study to this, reported by
Clemson et al. [1], Goldmann visual field
improvement was analyzed in 13 eyes, 9 eyes
had improved visual fields, while 2 eyes lost
visual field area and 2 eyes had no change in the
visual field. The authors reported that a few
patients experienced further vision loss during
their 3-month follow-up; however, this was not
observed in our patient series. Assuming typical
loss in the visual field in RP [8, 9, 12], any
improvement in the visual field should be
considered clinically significant.
While the results presented here are
promising, this study has several limitations:
only 10 patients were analyzed and the length
of follow-up was brief (an average of 3 months).
Furthermore, the patients were not genetically
characterized nor was their type of RP, due to
the potential role they may play in the
therapeutic response.
CONCLUSION
This case series adds to the emerging knowledge
on the role of VPA in the treatment of RP,
meriting further study in larger groups of
patients and for longer treatment periods.
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